AB Science SA (ABSCF)
OTHER OTC:ABSCF
ABSCF Stock Chart & Stats
$1.45
$0.10(12.50%)
At close: 4:00 PM EST
$1.45
$0.10(12.50%)
Day’s Range― - ―
52-Week Range$1.12 - $1.45
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$71.72M
Enterprise Value$61.32M
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 25, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding69,776,230
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue52.23
Enterprise Value/Gross Profit85.17
Enterprise Value/Ebitda-18.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$1.40M
Bulls Say, Bears Say
Bulls Say
Leverage ReductionA sharp reduction in gross debt to about €1.1M by 2025 materially lowers interest and refinancing pressure, improving solvency headroom. This structural deleveraging increases financial flexibility and reduces near-term funding needs, helping sustain R&D investment capacity over coming quarters.
Improving Revenue TrendConsistent year-on-year revenue increases, including ~14% growth in 2025, signal improving commercial traction or trial/partnership progress. A durable upward revenue trajectory supports scaling opportunities, validates development progress, and reduces reliance solely on financing if growth persists.
Diversified Clinical Focus (masitinib)A single molecule pursued across multiple therapeutic areas (oncology, inflammatory, neurological) spreads clinical and commercial risk and creates multiple potential approval and revenue pathways. Structural diversification of indications enhances long-term upside if one or more programs succeed.
Bears Say
Negative Shareholder EquityPersistently negative shareholder equity is a fundamental solvency red flag that constrains strategic options. It heightens financing risk, can limit access to credit or collaboration terms, and makes the company highly sensitive to further losses or adverse trial outcomes over the next several quarters.
Resumed Cash BurnReturn to multi-million euro negative operating and free cash flows in 2025 signals renewed funding pressure. Ongoing cash burn erodes runway, increases likelihood of near-term financing or dilutive capital raises, and can force cutbacks to R&D or slower development timelines if not addressed.
Persistent UnprofitabilityDeep, multi-year losses indicate the business is far from breakeven and dependent on external capital. Persistent unprofitability weakens internal cash generation, elevates solvency risk, and constrains the company's ability to self-fund trials or commercialization without diluting shareholders or securing partnerships.
AB Science SA News
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was $1.12 and its highest was $1.45 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is $71.72M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 103 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -$0.081 earnings per share for the quarter, the consensus estimate of -$0.081 by $0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.08.
How many shares outstanding does AB Science SA have?
AB Science SA has 69,776,230 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -$0.081 in its last earnings report, expectations of -$0.081. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in ABSCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.